MAPT and Alzheimer disease: A phase 2 study using a p38 inhibitor, Neflamapimod,showed that suppression of p38 can be a potential therapeutic strategyto treat AD.36 Although it has failed toaccomplish the primary end point in clinical trials, treatment withNeflamapimod resulted in a significant decrease of p-tau and totaltau in CSF and improvement of episodic memory function, as determinedby the Hopkins verbal learning test.12,37,38 In particular, synaptic dysfunction was reportedto be significantly improved.